Mineralys Therapeutics Inc [NASDAQ: MLYS] surged by $0.24 during the normal trading session on Thursday and reaching a high of $14.63 during the day while it closed the day at $14.54.
Mineralys Therapeutics Inc stock has also gained 3.86% of its value over the past 7 days. However, MLYS stock has inclined by 3.86% in the 3 months of the year. Over the past six months meanwhile, it has gained 16.13% and gained 19.47% year-on date.
The market cap for MLYS stock reached $947.65 million, with 64.88 million shares outstanding and 40.61 million shares in the current float. Compared to the average trading volume of 875.05K shares, MLYS reached a trading volume of 349918 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mineralys Therapeutics Inc [MLYS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MLYS shares is $36.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MLYS stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Mineralys Therapeutics Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 11, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 10, 2024, representing the official price target for Mineralys Therapeutics Inc stock. Previously, the target price had yet another raise to $30, while Goldman analysts kept a Buy rating on MLYS stock.
The Price to Book ratio for the last quarter was 2.76, with the Price to Cash per share for the same quarter was set at 5.26.
MLYS stock trade performance evaluation
Mineralys Therapeutics Inc [MLYS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.86. With this latest performance, MLYS shares dropped by -10.14% in over the last four-week period, additionally plugging by 16.13% over the last 6 months – not to mention a rise of 18.12% in the past year of trading.
Mineralys Therapeutics Inc [MLYS]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -53.69%, with Return on Assets sitting at -53.69%.
Earnings per share (EPS) analysis for Mineralys Therapeutics Inc [MLYS] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MLYS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mineralys Therapeutics Inc go to 2.14%.
Mineralys Therapeutics Inc [MLYS]: Institutional Ownership
There are presently around $98.73%, or 100.19% of MLYS stock, in the hands of institutional investors. The top three institutional holders of MLYS stocks are: CATALYS PACIFIC, LLC with ownership of 9.19 million shares, which is approximately 18.629%. SAMSARA BIOCAPITAL, LLC, holding 5.07 million shares of the stock with an approximate value of $$59.38 million in MLYS stocks shares; and SAMSARA BIOCAPITAL, LLC, currently with $$56.76 million in MLYS stock with ownership which is approximately 9.8285%.
